# Chai Discovery

Source: https://onco.cc/companies/chai-discovery/  
OnCo record `chai-discovery` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Makes Chai-1 and Chai-2, open-weight structure models used for antibody and binder design.

## Summary

Chai Discovery, based in San Francisco, makes Chai-1 and Chai-2, open-weight structure prediction models used for antibody and binder design. Chai-1, released in 2024, matched AlphaFold 3 on many benchmarks with open weights for non-commercial use, and Chai-2, released in 2025, reported zero-shot de novo antibody hit rates far above earlier methods. OnCo links it to the Chai-1 and Chai-2 technology record. Whether high computational hit rates translate into antibodies that behave in patients is the open question. Chai-1 and Chai-2 have their own technology page.

## Fields

- Kind: Company
- Last checked: 2026-09-08
- Tags: ai; protein-design
- HQ: San Francisco, CA
- Type: ai-software
- Website: https://www.chaidiscovery.com

## Sources

- Official website: https://www.chaidiscovery.com

## Connected records

- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/), [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- technologies: [Chai-1 / Chai-2](https://onco.cc/technologies/chai-1/)
- roadmaps: [Drug discovery roadmap: screening in mice → maps of dependency → designing in silico](https://onco.cc/roadmaps/drug-discovery-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/chai-discovery.json